CY1110173T1 - Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης - Google Patents

Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης

Info

Publication number
CY1110173T1
CY1110173T1 CY20091100116T CY091100116T CY1110173T1 CY 1110173 T1 CY1110173 T1 CY 1110173T1 CY 20091100116 T CY20091100116 T CY 20091100116T CY 091100116 T CY091100116 T CY 091100116T CY 1110173 T1 CY1110173 T1 CY 1110173T1
Authority
CY
Cyprus
Prior art keywords
estra
benzodioxol
dien
propynyl
hydroxy
Prior art date
Application number
CY20091100116T
Other languages
Greek (el)
English (en)
Inventor
Cornelis Sennef
Bwmm Bernardus Peeters
Original Assignee
N.V. Organon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N.V. Organon filed Critical N.V. Organon
Publication of CY1110173T1 publication Critical patent/CY1110173T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20091100116T 2001-10-26 2009-02-02 Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης CY1110173T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204072 2001-10-26
EP06101005A EP1652526B1 (en) 2001-10-26 2002-10-21 Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder

Publications (1)

Publication Number Publication Date
CY1110173T1 true CY1110173T1 (el) 2015-01-14

Family

ID=8181136

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100116T CY1110173T1 (el) 2001-10-26 2009-02-02 Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης

Country Status (26)

Country Link
US (1) US20040266863A1 (https=)
EP (2) EP1652526B1 (https=)
JP (1) JP4647909B2 (https=)
KR (1) KR20050038580A (https=)
CN (1) CN100531738C (https=)
AT (2) ATE317700T1 (https=)
AU (1) AU2002348996B2 (https=)
BR (1) BR0213466A (https=)
CA (1) CA2463446C (https=)
CY (1) CY1110173T1 (https=)
DE (2) DE60230936D1 (https=)
DK (1) DK1652526T3 (https=)
EC (1) ECSP045080A (https=)
ES (1) ES2319563T3 (https=)
HR (1) HRP20040370B1 (https=)
HU (1) HUP0500070A3 (https=)
IL (2) IL161248A0 (https=)
IS (1) IS2702B (https=)
MX (1) MXPA04003781A (https=)
NO (1) NO332978B1 (https=)
NZ (1) NZ532429A (https=)
PL (1) PL206687B1 (https=)
PT (1) PT1652526E (https=)
RU (1) RU2302245C2 (https=)
WO (1) WO2003037354A1 (https=)
ZA (1) ZA200403088B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080061A1 (en) * 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
BRPI0517847A (pt) * 2004-11-19 2008-10-21 Organon Nv combinação, usos de um inibidor de reabsorção de serotonina seletiva e de um antagonista do receptor de glicocorticóide, e, método para o tratamento de um indivìduo de uma espécie vertebrada sofrendo de depressão ou um distúrbio relacionado
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
WO2007131041A2 (en) * 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
WO2012106514A2 (en) * 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
WO2012145258A1 (en) * 2011-04-18 2012-10-26 Pop Test Cortisol Llc Hair loss treatment
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
DE4447401A1 (de) * 1994-12-23 1996-07-04 Schering Ag 14,17-C¶2¶-überbrückte Steroide
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
DE19727772A1 (de) * 1997-06-30 1999-01-28 Forschungszentrum Juelich Gmbh Magnetflußsensor mit ringförmiger Sonde
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
DE60232956D1 (de) * 2001-03-23 2009-08-27 Corcept Therapeutics Inc Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
WO2002096433A1 (en) * 2001-05-04 2002-12-05 Corcept Therapeutics, Inc. Methods for treating delirium using glucocorticoid receptor-specific antagonists
NZ531477A (en) * 2001-08-31 2006-10-27 Corcept Therapeutics Inc Use of a glucocorticoid receptor antagonist comprising a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton to decrease cognitive deterioration in adults with Down's syndrome

Also Published As

Publication number Publication date
ZA200403088B (en) 2005-01-24
HRP20040370A2 (en) 2004-08-31
IS7204A (is) 2004-03-31
EP1652526A3 (en) 2006-08-02
NO332978B1 (no) 2013-02-11
CA2463446A1 (en) 2003-05-08
PL206687B1 (pl) 2010-09-30
CN1582153A (zh) 2005-02-16
KR20050038580A (ko) 2005-04-27
AU2002348996B2 (en) 2008-06-05
HUP0500070A3 (en) 2012-09-28
RU2004116082A (ru) 2005-05-10
CN100531738C (zh) 2009-08-26
CA2463446C (en) 2010-02-23
JP2005521637A (ja) 2005-07-21
MXPA04003781A (es) 2004-07-30
WO2003037354A1 (en) 2003-05-08
IS2702B (is) 2010-11-15
EP1652526A2 (en) 2006-05-03
BR0213466A (pt) 2004-11-09
ATE420649T1 (de) 2009-01-15
ATE317700T1 (de) 2006-03-15
HK1087357A1 (en) 2006-10-13
EP1441739A1 (en) 2004-08-04
IL161248A0 (en) 2004-09-27
IL161248A (en) 2010-12-30
DE60230936D1 (de) 2009-03-05
ECSP045080A (es) 2004-06-28
NO20041651L (no) 2004-04-23
RU2302245C2 (ru) 2007-07-10
HRP20040370B1 (hr) 2012-09-30
JP4647909B2 (ja) 2011-03-09
DE60209248D1 (de) 2006-04-20
US20040266863A1 (en) 2004-12-30
EP1441739B1 (en) 2006-02-15
EP1652526B1 (en) 2009-01-14
ES2319563T3 (es) 2009-05-08
PT1652526E (pt) 2009-02-06
DK1652526T3 (da) 2009-05-18
NZ532429A (en) 2004-10-29
PL369261A1 (en) 2005-04-18
HUP0500070A2 (hu) 2005-04-28

Similar Documents

Publication Publication Date Title
CY1110173T1 (el) Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης
CY1105632T1 (el) Θεραπεια αντικαταστασης ορμονων με χρηση ενος συνδυασμου συζευγμενων οιστρογονων και οξικης μεδροξυπρογεστερονης
DK1090029T3 (da) 14,15-Cyclopropansteroider fra 19-norandrostan-rækken, fremgangsmåde til deres fremstilling, og farmaceutiske præparater indeholdende disse forbindelser
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
NO970309L (no) Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri
ATE493132T1 (de) Arzneimittel umfassend wenigstens ein gestagen
ATE345804T1 (de) Estrogenersatztherapie
DK1443966T3 (da) Fremgangsmåde til forebyggelse eller behandling af benigne gynækologiske lidelser
CO5261567A1 (es) Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas
AR049112A1 (es) Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
DK1487859T3 (da) Fremstillingsmetoder til at fremstille Eplerenon
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest
CY1105548T1 (el) Συνδυασμος του loteprednol και αγωνιστων του β2-αδρενοϋποδοχεως και η χρηση του με εισπνοες για την αγωγη του βρογχικου ασθματος
AR018313A1 (es) Kit anticonceptivo que comprende medios para la administracion diaria de un agente anticonceptivo, uso de un compuesto esteroide que tiene un perfil deactividad que combina inherentemente las actividades progestagenicas y estrogenicas y un metodo anticonceptivo
HUP9901474A2 (hu) Szekvenciális ösztrogén/progeszteron-antagonista kombináció hormonhelyettesítő terápiához
PY2168235A (es) Nueva composición de anticonceptivo oral de liberación modificada
ATE377020T1 (de) Kristallines gamma-lacton der17beta-hydroxy-
DK1937274T3 (da) Anvendelse af estradiolvalerat i kombination med dienogest til oral behandling af dysfunktionel uterin blødning i enhed med en oral kontraception
CY1110463T1 (el) Θεραπεια ορμονικης αντικαταστασης και καταθλιψης που περιλαμβανει διενογεστη
DK1910398T3 (da) 17-alfa-substituerede derivater af estradiol med sårhelende virkning